Savara Inc
SVRA2.645USD
+0.055+2.12%
交易中 （美东）报价延迟15分钟
456.80M总市值
亏损市盈率 TTM
关于 Savara Inc 公司
Savara Inc. 是一家临床阶段的生物制药公司，专注于罕见呼吸系统疾病。该公司的主导项目莫格拉司亭雾化器溶液 (molgramostim) 是一种吸入性生物制剂，具体来说是一种吸入性粒细胞巨噬细胞集落刺激因子 (GM-CSF)，处于 III 期开发阶段，用于治疗自身免疫性肺泡蛋白沉积症 (aPAP)。莫格拉司亭是一种重组人 GM-CSF 的吸入制剂，正在开发用于治疗 aPAP。莫格拉司亭雾化器溶液每天通过高效雾化器 eFlow 雾化器系统 (PARI Pharma GmbH) 吸入给药一次。肺泡蛋白沉积症 (PAP) 是一种罕见的肺部疾病，其特征是肺泡（或气囊）中积累了表面活性剂。该公司致力于推进 molgramostim aPAP 项目和 III 期 IMPALA-2 临床试验以及外包资本密集型业务。
公司简介
公司代码SVRA
公司名称Savara Inc
上市日期Jun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
员工数量59
证券类型Ordinary Share
年结日Jun 25
公司地址6836 Bee Cave Road
城市AUSTIN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编78746
电话151285113796
网址https://savarapharma.com/
公司代码SVRA
上市日期Jun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
持股股东
持股股东
占比
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
股东类型
持股股东
占比
Investment Advisor
33.05%
Venture Capital
22.55%
Hedge Fund
19.34%
Investment Advisor/Hedge Fund
16.33%
Private Equity
6.63%
Corporation
2.71%
Individual Investor
2.67%
Research Firm
1.67%
Bank and Trust
0.25%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
294
182.03M
105.32%
-6.77M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
2023Q2
170
92.45M
81.05%
-2.68M
2023Q1
166
87.31M
76.55%
-5.82M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
New Enterprise Associates (NEA)
24.47M
14.16%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
10.18%
+3.04M
+20.84%
Mar 31, 2025
TCG Crossover Management, LLC
12.36M
7.15%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
11.46M
6.63%
+2.80M
+32.35%
Mar 31, 2025
Vestal Point Capital, LP
11.00M
6.36%
+225.00K
+2.09%
Mar 31, 2025
VR Adviser, LLC
3.26M
1.88%
+3.26M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.71M
5.04%
+229.91K
+2.71%
Mar 31, 2025
The Vanguard Group, Inc.
8.10M
4.69%
-190.72K
-2.30%
Mar 31, 2025
Nantahala Capital Management, LLC
8.08M
4.67%
+550.12K
+7.31%
Mar 31, 2025
Deerfield Management Company, L.P.
7.96M
4.61%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Texas Capital Texas Small Cap Equity Index ETF
0.39%
iShares Micro-Cap ETF
0.07%
Texas Capital Texas Equity Index ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
Nuveen ESG Small-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
iShares Biotechnology ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.91%
Texas Capital Texas Small Cap Equity Index ETF
占比0.39%
iShares Micro-Cap ETF
占比0.07%
Texas Capital Texas Equity Index ETF
占比0.04%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
占比0.04%
Nuveen ESG Small-Cap ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
